tbuckley/cabot-search huggingface dataset:
Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL-Rearranged Leukemias
Authors: Alena Y. Zhang, Blaine W. Robinson, Li-San Wang, Kajia Kao, Lori Cory, Jeffrey S. Barrett, Susan Atlas, I-Ming Chen, Richard C. Harvey, Cheryl L. Willman, Meenakshi Devidas, Andrew J. Carroll, Stephen P. Hunger, Jonni S. Moore, Craig B. Thompson, Mondira Kundu, Carolyn A. Felix
Journal: Blood (2008)
Catecholamine-Induced Chest Pain Mimicking Infarction Due to an MIBG-Negative and DOPA-Positive Succinate Dehydrogenase Syndrome Subunit B–Related Pheochromocytoma
Authors: Alberto Mazza, Alice Ferretti, Antonella Paola Sacco, Domenico Rubello, Patrick M. Colletti
Journal: Clinical Nuclear Medicine (2017)

This 16-year-old boy presented with acute retrosternal pain possibly representing acute myocardial infarction. Cardiac enzymes were within reference ranges. There were marked increases in metanephrine to 3299 μg/24 h (reference, <400 μg/24 h), normetanephrine to 1309 μg/24 h (reference, 0-390 μg/24 h), and chromogranin A to 1605 ng/mL (reference, 0-150 μg/24 h). An incidental left adrenal mass was found during CTPA performed to exclude pulmonary embolism. I-MIBG scintigraphy was negative, and genetic screening detected SDHB (succinate dehydrogenase syndrome subunit B) gene mutation. Based on the gene mutation, F-DOPA PET/CT was performed, confirming a left-sided pheochromocytoma.
Molecular Characterization of NRG Gene, a Novel Partner, Fused to NUP98 Gene as a Result of the t(3;11)(q29q13;p15) Translocation in an Acute Myeloid/T Lymphocytic Leukemia.
Authors: Sai-Juan Chen, Yong-Jin Zhu, Qin Pan, Bai-Wei Gu, Zhi-Yao Xie, Xun Cai, Jin-Lan Pan, Ya-Fang Wu, Jing-Yi Shi, Guo Li, Shu-Min Xiong, Yong-Quan Xue, Zhu Chen, Sai-Juan Chen
Journal: Blood (2005)
High-Flow Oxygen vs Noninvasive Ventilation for Postextubation Respiratory Failure
Authors: Bruno Martins Tomazini, Bruno Adler Maccagnan Pinheiro Besen
Journal: JAMA (2017)

To the Editor The trial by Dr Hernández and colleagues1 found that postextubation high-flow conditioned oxygen therapy was not inferior to noninvasive ventilation (NIV) in high-risk patients. However, we believe that its results should be more carefully scrutinized.
The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose
Authors: Sandeep R.P. Kumar, Brad E. Hoffman, Cox Terhorst, Ype P. de Jong, Roland W. Herzog
Journal: Molecular Therapy (2017)

The liver continuously receives antigens from circulation and the gastrointestinal tract. A complex immune regulatory system has evolved in order to both limit inflammation and promote tolerance in the liver. Although in situ immune tolerance mechanisms enable successful gene therapy and liver transplantation, at the same time they facilitate chronic infections by pathogens such as hepatitis viruses. It is, however, poorly understood why hepatocytes infected with hepatitis viruses or transduced with adeno-associated virus (AAV)-based vectors may be rejected by CD8+ T cells several months later. We found that hepatic transfer of limited doses of an AAV-ovalbumin vector rapidly induced antigen-specific CD8+ T cells that only became functionally competent after >2 months. At this time, CD8+ T cells had downregulated negative checkpoint markers, e.g., the programmed death 1 [PD-1] receptor, and upregulated expression of relevant cytokines. At further reduced vector dose, only intrahepatic rather than systemic CD8+ T cell responses occurred, showing identical delay in antigen clearance. In contrast, PD-1-deficient mice rapidly cleared ovalbumin. Interestingly, higher vector dose directed sustained transgene expression without CD8+ T cell responses. Regulatory T cells, IL-10 expression, and Fas-L contributed to high-dose tolerance. Thus, viral vector doses profoundly impact CD8+ T cell responses.
Tacrolimus Given As an Alternative to Cyclosporin after Allogeneic HSCT in Case of Renal Impairment: A Prospective Pilot Study
Authors: Marie Y Detrait, Stéphane Morisset, Anne Beatrice Notarantonio, Pochon Cecile, Sabine Cohen, Catherine Rioufol, Gabrielle Roth Guepin, Maud D'Aveni, Adele Dhuyser, Sylvie Tarillon, Chapel Valerie, Marie t Rubio, Barraco Fiorenza, Mauricette Michallet
Journal: Blood (2016)
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
Authors: Andrea P. Myers, Virginia L. Filiaci, Yuping Zhang, Michael Pearl, Kian Behbakht, Vicky Makker, Parviz Hanjani, Susan Zweizig, James J Burke, Gordon Downey, Kimberly K. Leslie, Michael J. Birrer, Gini F. Fleming
Journal: Journal of Clinical Oncology (2015)

5592 Background: Rapamycin analogs have reproducible but modest efficacy in EC. Identification of molecular biomarkers that predict benefit from this class of agents could guide their clinical development. Methods: Fixed primary tissue and whole blood were collected prospectively from patients (pts) enrolled on GOG 248. DNA was isolated from macro-dissected tumors and blood; next–generation sequence analysis was performed on a panel of cancer related genes. Associations between clinical outcomes [Response rate (RR); 20% overall and progression-free survival (PFS); median 4.9 months] and common mutations (PTEN, PIK3CA, PIK3R1, KRAS, CTNNB1) and other PI3K/mTOR relevant mutations (AKT1, TSC1, TSC2, NF1, FBXW7) were explored. Results: Sequencing data was obtained from tumors of 55 of the 73 enrolled pts. Mutation rates were consistent with published reports: mutations in PTEN (45%), PIK3CA (29%), PIK3R1 (24%), K-RAS (16%), CTNNB1 (18%) were common and mutations in AKT1 (4%), TSC1 (2%), TSC2 (2%), NF1 (9%) and FBXW7 (4%) were less common. Increased PFS (HR 0.16; 95% CI 0.01-0.78) and RR (response difference 0.83; 95% CI 0.03-0.99) were noted for AKT1 mutation. An increase in PFS (HR 0.46; 95% CI 0.20-0.97) but not RR (response difference 0.00, 95% CI -0.34-0.34) was identified for CTNNB1 mutation. There were no statistically significant associations between mutations in PIK3CA, PTEN, PIK3R1, or KRAS and PFS or RR. Six patients had PFS > 15 months; of these, two had mutations in CTNNB1, and two had mutations in both CTNNB1 and AKT1. The pt with the longest PFS (on study over 46 cycles) had mutations of NF1, CTNNB1 and PIK3R1 in her tumor. Conclusions: Activating mutations in AKT1 are rare in EC, but may predict clinical benefit from temsirolimus. Consistent with a recent report of an association of CTNNB1 mutation with RR in a study of everolimus and letrozole, CTNNB1 mutations were associated with longer PFS on temsirolimus. Studies to elucidate the relationship of the Wnt/β-Catenin and mTOR pathway in EC are needed. Clinical trial information: NCT00729586.
Unrelated Allogeneic Stem Cell Transplantation for Severe Acquired Aplastic Anemia: Has Outcome Improved?.
Authors: Sebastien Maury, M.-Lorraine Balere-Appert, Zina Chir, J.-Michel Boiron, Claire Galambrun, Karima Yakouben, Pierre Bordigoni, Aude Marie-Cardine, Noel Milpied, Justina Kanold, Natacha Maillard, J.-Henri Bourhis, Alain Fischer, Patrick Lutz, Mauricette Michallet, Didier Blaise, Catherine Cordonnier, Colette Raffoux, Gerard Socie
Journal: Blood (2006)
Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway
Authors: Toshinobu Maki, Yasutaka Maeda, Noriyuki Sonoda, Hiroaki Makimura, Shinichiro Kimura, Sayaka Maeno, Ryoichi Takayanagi, Toyoshi Inoguchi
Journal: Metabolism (2017)
Multiple Skin Changes on the Lower Back of a Neonate
Authors: Deepa Patel, Leslie Castelo-Soccio
Journal: JAMA Pediatrics (2017)

An 11-day-old, full-term girl had multiple skin changes, including a red patch on the central lower back with a soft nodule located on top of the patch, as well as a pedunculated red papule positioned on top of the red stain and soft nodule. What is your diagnosis?
A Polymorphism Study on Detoxification and DNA Repair Genes in 700 MDS Patients Demonstrates An Association Between Genotype and An Aberrant Karyotype
Authors: C. Seedhouse, Stephanie Fischer, Christina Ganster, Christa Fonatsch, Peter Valent, Ulrich Germing, Nigel H. Russell, Detlef Haase
Journal: Blood (2008)
Unloading Shoes for Self-management of Knee Osteoarthritis
Authors: Howard Simon
Journal: Annals of Internal Medicine (2017)

Letters21 February 2017Unloading Shoes for Self-management of Knee OsteoarthritisHoward Simon, MDHoward Simon, MDFrom Case Western Reserve University School of Medicine, Cleveland, Ohio.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0631 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I read Hinman and colleagues' article (1) with interest. In 1905, Hoffman (2) compared the feet of barefoot and shoe-wearing populations. He found that, if you wear shoes, your first toe is deformed from the natural state by being deviated laterally. I attended a lecture in the 1970s that described this deformity and linked it to foot pain. Since then, I have advised my patients with foot pain and deformed toes to wear shoes that give their toes more space, to good effect.D'Août and associates (3) compared the pressure, while walking, in asymptomatic shoe-wearing and barefoot ...References1. Hinman RS, Wrigley TV, Metcalf BR, Campbell PK, Paterson KL, Hunter DJ, et al. Unloading shoes for self-management of knee osteoarthritis. A randomized trial. Ann Intern Med. 2016;165:381-9. [PMID: 27398991]. doi:10.7326/M16-0453 LinkGoogle Scholar2. Hoffmann P. Conclusions drawn from a comparative study of the feet of barefooted and shoe-wearing peoples. American Journal of Orthopedic Surgery. 1905;3:105-36. Google Scholar3. D'Août K, Pataky TC, De Clercq D, Aerts P. The effects of habitual footwear use: foot shape and function in native barefoot walkers. Footwear Science. 2009;1:81-94. doi:10.1080/19424280903386411 CrossrefGoogle Scholar4. Shakoor N, Block JA. Walking barefoot decreases loading on the lower extremity joints in knee osteoarthritis. Arthritis Rheum. 2006;54:2923-7. [PMID: 16947448] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Case Western Reserve University School of Medicine, Cleveland, Ohio.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0631. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUnloading Shoes for Self-management of Knee Osteoarthritis Rana S. Hinman , Tim V. Wrigley , Ben R. Metcalf , Penny K. Campbell , Kade L. Paterson , David J. Hunter , Jessica Kasza , Andrew Forbes , and Kim L. Bennell Unloading Shoes for Self-management of Knee Osteoarthritis Ryan T. Lewinson and Darren J. Stefanyshyn Unloading Shoes for Self-management of Knee Osteoarthritis Rana S. Hinman , Kade L. Paterson , Tim V. Wrigley , and Kim L. Bennell Metrics 21 February 2017Volume 166, Issue 4Page: 311KeywordsConflicts of interestDisclosureHipKneesOsteoarthritisPopulation statisticsUlcersWalking ePublished: 21 February 2017 Issue Published: 21 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Sensitivity for detecting PIK3CA mutations in early-stage breast cancer with droplet digital PCR.
Authors: Julia A. Beaver, Sasidharan Balukrishna, Danijela Jelovac, Michaela Jane Higgins, Stacie Jeter, Vered Stearns, Antonio C. Wolff, Jill Kessler, Dustin VanDenBerg, Patricia Valda Toro, Pedram Argani, Ben Ho Park
Journal: Journal of Clinical Oncology (2013)

11019 Background: PIK3CA is mutated in up to 30% of breast cancers. Classically somatic mutations are identified by Sanger sequencing of the primary tumor specimen. However third generation droplet digital PCR technologies offer a novel platform for quantitative mutation detection with improved sensitivity. Methods: Thirty stage I-III breast cancer patients were consented on an IRB-approved prospective repository study at Johns Hopkins for collection of their primary breast tumor specimen. Formalin-fixed paraffin embedded (FFPE) samples were analyzed by standard sequencing for three PIK3CA hotspot mutations. The DNA from these samples was then analyzed using the RainDrop digital PCR platform with TaqMan probes in a triplex format to simultaneously detect and quantitate hotspot mutations and genome equivalents. Results are expressed as a percentage of mutant to wild-type PIK3CA molecules for each sample. Results: Standard sequencing of all tumors (n=30) identified seven PIK3CA Exon 20 mutations (H1047R) and three Exon 9 mutations (E545K). Samples were scored as PIK3CA mutation positive by digital PCR if the tumor DNA contained at least 5% mutant molecules. All ten mutations identified by sequencing were verified by digital PCR with quantities of mutant molecules ranging from 20.3-55.6% in a given sample. Digital PCR identified additional PIK3CA mutations that were wild type by standard sequencing including three mutant Exon 20 samples, two mutant Exon 9 samples and one sample with an Exon 20 and Exon 9 mutation. Quantities of mutant molecules in these additional samples ranged from 5-28.9%. Conclusions: RainDrop digital PCR offers improved sensitivity and quantification for detecting PIK3CA mutations in FFPE samples using nanograms of DNA. Additional mutations identified by digital PCR may reflect genetic heterogeneity or possibly tissue contamination. The clinical utility of identifying a small proportion of mutations is unknown but may impact eligibility for targeted therapies and clinical trials. Ongoing studies will also address whether the identification of solid tumor mutations in circulating cell-free plasma DNA by digital PCR can improve diagnostics and aid in therapeutic decisions.
Protesters march to stop NHS from being “hung out to dry”
Authors: Anne Gulland
Journal: BMJ (2017)

Mark Thomas

Thousands of NHS staff and patients joined a march in London to protest at continuing cuts to the health service in England.

The organiser, Health Campaigns Together, an umbrella organisation of NHS pressure groups, said that around 250 000 people joined the march from Tavistock Square in Bloomsbury, where …
Abstract P1-02-01: Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer – Longer follow-up of a proof-of-principle study
Authors: NC Turner, I Garcia-Murillas, N Chopra, M Beaney, L Kilburn, R Cutts, P Osin, A Nerurkar, G Schiavon, S Hrebien, J Bliss, M Dowsett, I Smith
Journal: Cancer Research (2017)

Abstract Background In a previous proof-of-principle study we demonstrated that detection of circulating tumour DNA (ctDNA) in the adjuvant setting, after completion of surgery and chemotherapy for early stage breast cancer, was associated with a high risk of early relapse. Here we present longer follow-up of the same series, to define the predictive power of ctDNA analysis for disease free survival, and assess the potential to predict overall survival. Methods We recruited a cohort of 55 women presenting with early stage, primary breast cancer, who were all scheduled to receive neo-adjuvant chemotherapy. The primary tumour was sequenced to identify somatic mutations, identifying at least one mutation in 43 patients. Mutations were tracked with digital PCR to identify ctDNA, in plasma samples taken either at a single post-surgical time point (2-6 weeks post-surgery) or with serial plasma samples taken every 6 months in the adjuvant setting. Results At a median 31.7 months follow-up, 42% (18/43) patients had relapsed. Detection of ctDNA at the single post-surgical time point was associated with poor disease free survival, HR=13.6 95%CI (4.5, 41.2) p&amp;lt;0.001, and overall survival HR=84.7 95%CI (9.8, 730.4) p&amp;lt;0.001. All patients with ctDNA detected in a single post-surgical time point relapsed and died in the follow-up period (7/7, 100% specificity), although the single post-surgery time point had modest 39% (7/18) sensitivity for relapse. Detection of ctDNA at any point in serial sampling was associated with poor disease free survival HR=25.7 95%CI (8.3, 79.8) p&amp;lt;0.001 and overall survival HR=47.1 95%CI (6.1, 366.1) p&amp;lt;0.001. All patients with ctDNA detected in a serial mutation tracking relapsed in the follow-up period (14/14, 100% specificity), with 78% (14/18) sensitivity for relapse. Sensitivity was limited by 3 cases of brain only relapse and one case of solitary ovarian relapse. Detection of ctDNA in serial sampling had a median lead-time of 8.1 months over clinical relapse. Conclusion Detection of ctDNA in the adjuvant setting has a high predictive power for future relapse and death from breast cancer. Therapeutic trials are required to determine whether mutation tracking identifies relapse sufficiently early to allow for further adjuvant therapy. Citation Format: Turner NC, Garcia-Murillas I, Chopra N, Beaney M, Kilburn L, Cutts R, Osin P, Nerurkar A, Schiavon G, Hrebien S, Bliss J, Dowsett M, Smith I. Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer – Longer follow-up of a proof-of-principle study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-02-01.
Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients
Authors: Olivier Aubert, Alexandre Loupy, Luis Hidalgo, Jean-Paul Duong van Huyen, Sarah Higgins, Denis Viglietti, Xavier Jouven, Denis Glotz, Christophe Legendre, Carmen Lefaucheur, Philip F. Halloran
Journal: Journal of the American Society of Nephrology (2017)

Antibody-mediated rejection (ABMR) can occur in patients with preexisting anti-HLA donor-specific antibodies (DSA) or in patients who develop de novo DSA. However, how these processes compare in terms of allograft injury and outcome has not been addressed. From a cohort of 771 kidney biopsy specimens from two North American and five European centers, we performed a systematic assessment of clinical and biologic parameters, histopathology, circulating DSA, and allograft gene expression for all patients with ABMR ( n =205). Overall, 103 (50%) patients had preexisting DSA and 102 (50%) had de novo DSA. Compared with patients with preexisting DSA ABMR, patients with de novo DSA ABMR displayed increased proteinuria, more transplant glomerulopathy lesions, and lower glomerulitis, but similar levels of peritubular capillaritis and C4d deposition. De novo DSA ABMR was characterized by increased expression of IFN γ -inducible, natural killer cell, and T cell transcripts, but less expression of AKI transcripts compared with preexisting DSA ABMR. The preexisting DSA ABMR had superior graft survival compared with the de novo DSA ABMR (63% versus 34% at 8 years after rejection, respectively; P &lt;0.001). After adjusting for clinical, histologic, and immunologic characteristics and treatment, we identified de novo DSA ABMR (hazard ratio [HR], 1.82 compared with preexisting DSA ABMR; 95% confidence interval [95% CI], 1.07 to 3.08; P =0.03); low eGFR (&lt;30 ml/min per 1.73 m 2 ) at diagnosis (HR, 3.27; 95% CI, 1.48 to 7.23; P &lt;0.001); ≥0.30 g/g urine protein-to-creatinine ratio (HR, 2.44; 95% CI, 1.47 to 4.09; P &lt;0.001); and presence of cg lesions (HR, 2.25; 95% CI, 1.34 to 3.79; P =0.002) as the main independent determinants of allograft loss. Our findings support the transplant of kidneys into highly sensitized patients and should encourage efforts to monitor patients for de novo DSA.
The Frequency and Characteristics of the Ribosomal Protein L5 (RPL5) and Ribosomal Protein L11 (RPL11) Gene Mutations in Patients with Diamond-Blackfan Anemia in the Czech National Registry
Authors: Dagmar Pospisilova, Radek Cmejla, Jana Cmejlova, Helena Handrkova, Jan Stary, Zdenka Cerna
Journal: Blood (2008)
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
Authors: Caitlin D. Lowery, Alle B. VanWye, Michele Dowless, Wayne Blosser, Beverly L. Falcon, Julie Stewart, Jennifer Stephens, Richard P. Beckmann, Aimee Bence Lin, Louis F. Stancato
Journal: Clinical Cancer Research (2017)

Purpose: Checkpoint kinase 1 (CHK1) is a key regulator of the DNA damage response and a mediator of replication stress through modulation of replication fork licensing and activation of S and G2-M cell-cycle checkpoints. We evaluated prexasertib (LY2606368), a small-molecule CHK1 inhibitor currently in clinical testing, in multiple preclinical models of pediatric cancer. Following an initial assessment of prexasertib activity, this study focused on the preclinical models of neuroblastoma.Experimental Design: We evaluated the antiproliferative activity of prexasertib in a panel of cancer cell lines; neuroblastoma cell lines were among the most sensitive. Subsequent Western blot and immunofluorescence analyses measured DNA damage and DNA repair protein activation. Prexasertib was investigated in several cell line-derived xenograft mouse models of neuroblastoma.Results: Within 24 hours, single-agent prexasertib promoted γH2AX-positive double-strand DNA breaks and phosphorylation of DNA damage sensors ATM and DNA-PKcs, leading to neuroblastoma cell death. Knockdown of CHK1 and/or CHK2 by siRNA verified that the double-strand DNA breaks and cell death elicited by prexasertib were due to specific CHK1 inhibition. Neuroblastoma xenografts rapidly regressed following prexasertib administration, independent of starting tumor volume. Decreased Ki67 and increased immunostaining of endothelial and pericyte markers were observed in xenografts after only 6 days of exposure to prexasertib, potentially indicating a swift reduction in tumor volume and/or a direct effect on tumor vasculature.Conclusions: Overall, these data demonstrate that prexasertib is a specific inhibitor of CHK1 in neuroblastoma and leads to DNA damage and cell death in preclinical models of this devastating pediatric malignancy. Clin Cancer Res; 23(15); 4354-63. ©2017 AACR.
Minimal Residual Disease Does Not Impact Risk of Relapse in Myeloablative Umbilical Cord Blood Transplant Recipients: Comparison with Matched and Mismatched Unrelated Transplants
Authors: Filippo Milano, Ted A. Gooley, Brent L. Wood, Ann E Woolfrey, Effie W. Petersdorf, Frederick R. Appelbaum, Colleen Delaney
Journal: Blood (2014)
Closed Valvuloplasty for Mitral Stenosis
Authors: Laurence B. Ellis, Dwight E. Harken
Journal: New England Journal of Medicine (1964)

SINCE our first report of successful surgery for mitral stenosis in 19481 operations for the correction of this lesion have been carried out in sufficiently large numbers and long enough for valid statistical deductions. The benefits conferred by surgery, and factors influencing both improvement and deterioration after initial improvement, can be assessed. We have previously made progress reports on the late results of our initial consecutive series of patients.2 , 3 The current report extends this series by an additional 571 patients operated on up to November 1, 1961, and an additional three years of follow-up study.At present surgeons disagree about . . .
Expression of T-Lineage Affiliated Transcripts and TCR Rearrangements in Hypogranular Variant Acute Promyelocytic Leukemia (APL): Implications for the Cellular Target of the t(15;17).
Authors: Elise Chapiro, Vahid Asnafi, Eric Delabesse, Frédéric Davi, Elizabeth Nugent, Françoise Valensi, Khiera Beldjord, David Grimwade, Elizabeth A. Macintyre
Journal: Blood (2004)
Repeated Application of Sequence-Specific SiRNA Molecules Leads to an Effective Downmodulation of All Clinically Relevant bcr-abl Gene Variants.
Authors: Lara Wohlbold, Heiko van der Kuip, Alexandra Moehring, Galit Granot, Moshe Oren, Hans-Peter Vornlocher, Walter E. Aulitzky
Journal: Blood (2004)